The top performing VapA Rhodococcus Equi Antibody.

Licensed by the USDA in 2009, ReSolution Rhodococcus Equi Antibody is an efficacious aid in the control of Rhodococcus equi. Our research showed that the administration of ReSolution Rhodococcus Equi Antibody within the first three days of life increased Virulence-Associated Plasmid A (VapA) titers for R. equi pneumonia. VapA has been attributed to the virulence of the disease. Rhodococcus Equi Antibody that is high in VapA means reduced severity of disease in foals. Administration of ReSolution Rhodococcus Equi Antibody early in life statistically reduced the severity of radiographic lung lesions after infection and reduced morbidity attributable to infection with R. equi.

In 2019, researchers at Texas A&M published “Transfusion With 2 L of Hyperimmune Plasma is Superior to Transfusion of 1 L or Less for Protecting Foals Against Subclinical Pneumonia” (Kahn, et al., 2019). In summary, 68% of foals treated with 1 L of Rhodococcus equi hyperimmune plasma (REHIP) showed protection against R. equi pneumonia. That percentage increased to 80% when given 2 L of REHIP. Researchers observed a whopping 20% increase in protection.

In 2016 the Gluck Equine Research Center published another study proving the ability of Rhodococcus Equi Antibody to aid in the prevention of clinical rhodococcal pneumonia in neonatal foals after experimental challenge. This report noted high levels of variance in the number of antibody content between commercially available Hyperimmune(HI) products. To paraphrase, not all competition is equally potent!

In 2014, a third party study was conducted by the Gluck Equine Research Center that evaluated commercial R. equi antibody products (Sanz, et al). The study evaluated the distribution of VapA-specific IgG and IgG subclasses in commercially available products. ReSolution Rhodococcus Equi Antibody showed to be statistically significantly higher than competitor’s products (with a p-value < 0.05) when VapA-specific IgGa levels were measured (4x higher!). Mg Biologics has developed a VapA potency test and all our serials have a minimum release titer of 1:10,000 (as published by Caston, et al). This study confirms that with minimum VapA titer levels at 1:10,000, Mg’s ReSolution is the top performer regarding VapA Rhodococcus Equi Antibody.

Mg continues to be the number one researched R. equi antibody manufacturer in the country. We manufacture the highest published antibody titer and that is why we are the gold standard for Rhodococcus equi antibody products in this industry.